Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs
- PMID: 18063025
- DOI: 10.1016/S0140-6736(07)61699-7
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs
Abstract
In 2005, a global goal of reducing chronic disease death rates by an additional 2% per year was established. Scaling up coverage of evidence-based interventions to prevent cardiovascular disease in high-risk individuals in low-income and middle-income countries could play a major part in reaching this goal. We aimed to estimate the number of deaths that could be averted and the financial cost of scaling up, above current coverage levels, a multidrug regimen for prevention of cardiovascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries. Identification of individuals was limited to those already accessing health services, and treatment eligibility was based on the presence of existing cardiovascular disease or absolute risk of cardiovascular disease by use of easily measurable risk factors. Over a 10-year period, scaling up this multidrug regimen could avert 17.9 million deaths from cardiovascular disease (95% uncertainty interval 7.4 million-25.7 million). 56% of deaths averted would be in those younger than 70 years, with more deaths averted in women than in men owing to larger absolute numbers of women at older ages. The 10-year financial cost would be US$47 billion ($33 billion-$61 billion) or an average yearly cost per head of $1.08 ($0.75-1.40), ranging from $0.43 to $0.90 across low-income countries and from $0.54 to $2.93 across middle-income countries. This package could effectively meet three-quarters of the proposed global goal with a moderate increase in health expenditure.
Similar articles
-
The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.Eur J Cardiovasc Prev Rehabil. 2006 Aug;13(4):523-8. doi: 10.1097/01.hjr.0000230098.63277.61. Eur J Cardiovasc Prev Rehabil. 2006. PMID: 16874140
-
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.Lancet. 2006 Aug 19;368(9536):679-86. doi: 10.1016/S0140-6736(06)69252-0. Lancet. 2006. PMID: 16920473 Free PMC article. Review.
-
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013. Clin Ther. 2009. PMID: 20110032
-
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.Clin Ther. 2009 Oct;31(10):2189-203; discussion 2150-1. doi: 10.1016/j.clinthera.2009.10.015. Clin Ther. 2009. PMID: 19922890
-
The burden and costs of chronic diseases in low-income and middle-income countries.Lancet. 2007 Dec 8;370(9603):1929-38. doi: 10.1016/S0140-6736(07)61696-1. Lancet. 2007. PMID: 18063029 Review.
Cited by
-
Community-driven citizen science approach to explore cardiovascular disease risk perception, and develop prevention advocacy strategies in sub-Saharan Africa: a programme protocol.Res Involv Engagem. 2021 Feb 26;7(1):11. doi: 10.1186/s40900-020-00246-x. Res Involv Engagem. 2021. PMID: 33637131 Free PMC article.
-
Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India.PLoS One. 2016 May 9;11(5):e0155293. doi: 10.1371/journal.pone.0155293. eCollection 2016. PLoS One. 2016. PMID: 27159055 Free PMC article.
-
Education, household wealth and blood pressure in Albania, Armenia, Azerbaijan and Ukraine: findings from the Demographic Health Surveys, 2005-2009.Eur J Intern Med. 2013 Mar;24(2):117-26. doi: 10.1016/j.ejim.2012.11.004. Epub 2012 Dec 14. Eur J Intern Med. 2013. PMID: 23246126 Free PMC article.
-
Comparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohort.Anatol J Cardiol. 2017 Feb;17(2):92-96. doi: 10.14744/AnatolJCardiol.2016.6965. Epub 2016 Sep 28. Anatol J Cardiol. 2017. PMID: 27684519 Free PMC article.
-
Primary stroke prevention worldwide: translating evidence into action.Lancet Public Health. 2022 Jan;7(1):e74-e85. doi: 10.1016/S2468-2667(21)00230-9. Epub 2021 Oct 29. Lancet Public Health. 2022. PMID: 34756176 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical